BRPI0516957A - formulação farmacêutica estabilizada de agente de leucotrieno b4 (ltb4) - Google Patents

formulação farmacêutica estabilizada de agente de leucotrieno b4 (ltb4)

Info

Publication number
BRPI0516957A
BRPI0516957A BRPI0516957-7A BRPI0516957A BRPI0516957A BR PI0516957 A BRPI0516957 A BR PI0516957A BR PI0516957 A BRPI0516957 A BR PI0516957A BR PI0516957 A BRPI0516957 A BR PI0516957A
Authority
BR
Brazil
Prior art keywords
ltb4
pharmaceutical formulation
stabilized pharmaceutical
agent
leukotriene agent
Prior art date
Application number
BRPI0516957-7A
Other languages
English (en)
Inventor
Pierre Borgeat
Original Assignee
Ltb4 Sweden Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ltb4 Sweden Ab filed Critical Ltb4 Sweden Ab
Publication of BRPI0516957A publication Critical patent/BRPI0516957A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

FORMULAçãO FARMACêUTICA ESTABILIZADA DE AGENTE DE LEUCOTRIENO B~ 4~ (LTB~ 4~). A presente invenção refere-se a uma nova formulação farmacêutica compreendendo um agente de LTB~ 4~ em um pH alcalino eficaz para estabilizar o agente de LTB~ 4~ e proporcionar uma formulação com uma vida útil aumentada. A formulação da presente invenção tem uma vida útil aumentada, de preferência de pelo menos 24 meses.
BRPI0516957-7A 2004-09-20 2005-09-20 formulação farmacêutica estabilizada de agente de leucotrieno b4 (ltb4) BRPI0516957A (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US61096204P 2004-09-20 2004-09-20
US63500904P 2004-12-13 2004-12-13
US63548204P 2004-12-14 2004-12-14
PCT/IB2005/002781 WO2006032977A2 (en) 2004-09-20 2005-09-20 Stabilized leukotriene b4 (ltb4) agent pharmaceutical

Publications (1)

Publication Number Publication Date
BRPI0516957A true BRPI0516957A (pt) 2008-09-30

Family

ID=35902513

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0516957-7A BRPI0516957A (pt) 2004-09-20 2005-09-20 formulação farmacêutica estabilizada de agente de leucotrieno b4 (ltb4)

Country Status (23)

Country Link
US (1) US8664271B2 (pt)
EP (1) EP1796730B1 (pt)
JP (1) JP4767256B2 (pt)
KR (1) KR101109735B1 (pt)
CN (1) CN101039698B (pt)
AT (1) ATE474603T1 (pt)
AU (1) AU2005286161B2 (pt)
BR (1) BRPI0516957A (pt)
CA (1) CA2581156C (pt)
CY (1) CY1110841T1 (pt)
DE (1) DE602005022462D1 (pt)
DK (1) DK1796730T3 (pt)
EA (1) EA012982B1 (pt)
ES (1) ES2349410T3 (pt)
HK (1) HK1103652A1 (pt)
NO (1) NO20071977L (pt)
NZ (1) NZ553982A (pt)
PL (1) PL1796730T3 (pt)
PT (1) PT1796730E (pt)
SI (1) SI1796730T1 (pt)
TW (1) TWI361078B (pt)
UA (1) UA96257C2 (pt)
WO (1) WO2006032977A2 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1840114A1 (en) * 2006-03-30 2007-10-03 LTB4 Sweden AB Crystalline Leukotriene B4
CN102435443B (zh) * 2011-09-08 2014-04-02 中国汽车技术研究中心 汽车催化器快速老化数据采集系统
JP6483593B2 (ja) * 2015-03-06 2019-03-13 アークレイ株式会社 血液検査装置および血液検査方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0179959A1 (en) 1982-04-20 1986-05-07 Merck Frosst Canada Inc. Conjugates of leukotrienes with proteins
US4568559A (en) * 1984-02-06 1986-02-04 Biotek, Inc. Composite core coated microparticles and process of preparing same
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4876505A (en) * 1988-05-27 1989-10-24 Westinghouse Electric Corp. Apparatus and method for monitoring steam turbine shroud clearance
US20040132820A1 (en) 1996-02-15 2004-07-08 Jean Gosselin Agents with leukotriene B4-like antiviral (DNA) and anti-neoplastic activities
US5789441A (en) * 1996-02-15 1998-08-04 Virocell Inc. Leukotriene B4 as an antiviral and anti-neoplastic agent
US5780055A (en) * 1996-09-06 1998-07-14 University Of Maryland, Baltimore Cushioning beads and tablet comprising the same capable of forming a suspension
US5909734A (en) 1996-12-03 1999-06-08 Regents Of The University Of Michigan Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense
DE60232413D1 (en) 2001-07-05 2009-07-02 Ltb4 Sweden Ab Ltb4 als adjuvans für impfstoffe
WO2003105823A1 (en) 2002-06-14 2003-12-24 Alcon, Inc. Use of hydroxyeicosatetraenoic acid compounds to treat dry mouth

Also Published As

Publication number Publication date
CN101039698B (zh) 2011-11-09
EP1796730A2 (en) 2007-06-20
EA012982B1 (ru) 2010-02-26
KR20070085277A (ko) 2007-08-27
CA2581156A1 (en) 2006-03-30
HK1103652A1 (en) 2007-12-28
TW200626175A (en) 2006-08-01
DE602005022462D1 (de) 2010-09-02
PT1796730E (pt) 2010-10-26
DK1796730T3 (da) 2010-11-01
AU2005286161B2 (en) 2010-09-09
ES2349410T3 (es) 2011-01-03
US20060063837A1 (en) 2006-03-23
EP1796730B1 (en) 2010-07-21
JP2008513431A (ja) 2008-05-01
WO2006032977A2 (en) 2006-03-30
CN101039698A (zh) 2007-09-19
AU2005286161A1 (en) 2006-03-30
PL1796730T3 (pl) 2010-12-31
KR101109735B1 (ko) 2012-02-17
TWI361078B (en) 2012-04-01
US8664271B2 (en) 2014-03-04
CA2581156C (en) 2011-07-12
WO2006032977A3 (en) 2006-07-13
UA96257C2 (uk) 2011-10-25
CY1110841T1 (el) 2015-06-10
EA200700676A1 (ru) 2007-10-26
SI1796730T1 (sl) 2010-12-31
NO20071977L (no) 2007-04-18
ATE474603T1 (de) 2010-08-15
JP4767256B2 (ja) 2011-09-07
NZ553982A (en) 2009-09-25

Similar Documents

Publication Publication Date Title
BR0207930A (pt) Composições farmacêuticas lìquidas com sabor mascarado
BRPI0415121A (pt) material particulado, forma de dosagem sólida, método para fabricar a mesma, e, uso de um material particulado ou de uma forma de dosagem sólida
IL163552A (en) Conjugates of biologically active compounds, uses thereof and pharmaceutical compositions comprising the same
WO2007056424A3 (en) Controlled-release emulsion compositions
DE60105448D1 (de) Feste dispersionen mit nitrataktiven wirkstoffen
WO2005065657A3 (en) Solid compositions of low-solubility drugs and poloxamers
BR0214254A (pt) Pó filmogênio micronizado e composição farmacêutica, cosmética ou neutracêutica
WO2002051424A8 (fr) Medicaments contre les defaillances articulaires
ATE485049T1 (de) Physiologisch aktive zusammensetzung gegen diabetes
AR038207A1 (es) Composicion farmaceutica dispersable oralmente de agomelatina
BRPI0410555A (pt) preparação sólida
BR9810495A (pt) Composição farmacêutica
WO2005074925A8 (en) Compositions substantially free of galactomannan containing piperacillin and tazobactam
NZ547587A (en) Pharmaceutical compositions and methods for insulin treatment
MY143561A (en) Pregabalin composition
DE602006019320D1 (de) Biologisch wirksame zusammensetzung mit ethylcellulose
WO2006121717A3 (en) Skin care compositions containing idebenone
BRPI0611526A2 (pt) composição tópica contendo gelatina
EE05124B1 (et) Toimeainena dotsetakseeli v?i selle hdraati sisaldava kompositsiooni kasutamine
BRPI0516957A (pt) formulação farmacêutica estabilizada de agente de leucotrieno b4 (ltb4)
WO2004039326A3 (en) Propofol with cysteine
ATE409040T1 (de) Kombination enthaltend substanzen mit npy- rezeptor affinität und substanzen mit 5-ht6- rezeptor affinität
BRPI0504082A (pt) emulsões refrescantes medicinais
FR2907682B1 (fr) Composition cosmetique et/ou pharmaceutique comprenant comme principe actif au moins un peptide et utilisation de ce peptide.
ATE359350T1 (de) Verdickte wässrige zusammensetzungen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]